Rigel Pharmaceuticals Appoints Dr. Mark Frohlich to Board
Dr. Mark Frohlich joins Rigel’s Board, bringing expertise in immunotherapy and oncology drug development.
Rigel Pharmaceuticals has appointed Dr. Mark W. Frohlich to its Board of Directors, strengthening its leadership with his extensive experience in immunotherapy and oncology drug development. With over 25 years in the field, Dr. Frohlich has played a pivotal role in advancing cellular immunotherapies, including his work at Juno Therapeutics and Dendreon Corporation. Currently, he serves as the CEO of Indapta Therapeutics, a biotech company developing allogeneic natural killer cell therapies. Rigel’s CEO, Raul Rodriguez, emphasized that Dr. Frohlich’s expertise in clinical development and portfolio strategy will be instrumental in advancing the company’s hematology and oncology pipeline.
Expressing his enthusiasm, Dr. Frohlich highlighted the promising potential of Rigel’s IRAK1/4 and IDH1 inhibitor programs, which are being developed for lower-risk myelodysplastic syndrome and glioma, respectively. His addition to the board is expected to support Rigel’s mission of bringing innovative treatment options to patients with unmet medical needs.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Discussion